The ESMO-MCBS Scorecards allows you to filter either by Agent, Tumour or Score giving priority to different criteria such as Agent and Tumour Type and Tumour sub-type and Tumour sub-group in the Curative or Non-curative setting. This content will be updated regularly and communicated to ESMO Members.
Treatment of adult patients with unresectable or metastatic HER2 positive breast cancer who have received one or more prior anti HER2 based regimensDESTINY-Breast03
Breast Cancer
Breast Cancer
HER2+
DESTINY-Breast03
4
PRELIMINARY SCORE
PFS
ADJUSTMENTS
FINAL SCORE
F2b
4
Durvalumab
Gemcitabine and cisplatin
Placebo + gemcitabine and cisplatin
In combination with gemcitabine and cisplatin is indicated for the first‑line treatment of adults with unresectable or metastatic biliary tract cancer (BTC).TOPAZ-1
Gastrointestinal Cancers
Biliary tract cancer
-
TOPAZ-1
4
PRELIMINARY SCORE
OS
ADJUSTMENTS
FINAL SCORE
F2a
4
Trastuzumab deruxtecan
-
Pysician's ChT choice (eribulin, capecitabine, gemcitabine, nab-paclitaxel, or paclitaxel)
Montherapy for the treatment of adult patients with unresectable or metastatic HER2‑low breast cancer who have received prior chemotherapy in the metastatic setting or developed disease recurrence during or within 6 months of completing adjuvant chemotherapyDESTINY-Breast04
Breast Cancer
Breast Cancer
HER2-low
DESTINY-Breast04
4
PRELIMINARY SCORE
OS
ADJUSTMENTS
FINAL SCORE
F2a
4
Darolutamide
ADT ((androgen deprivation therapy) + docetaxel
ADT + Docetaxel + placebo
For adult patients with metastatic hormone-sensitive prostate cancer (mHSPC) in combination with docetaxel and androgen deprivation therapyARASENS
Genitourinary Cancers
Prostate cancer
-
ARASENS
4
PRELIMINARY SCORE
OS
ADJUSTMENTS
FINAL SCORE
F2a
4
Cemiplimab
-
Single arm (Phase II)
For the treatment of adult patients with metastatic or locally advanced cutaneous squamous cell carcinoma (mCSCC or laCSCC) who are not candidates for curative surgery or curative radiationR2810-ONC-1423/R2810-ONC-1540
Skin Cancers
Cutaneous Squamous Cell Carcinoma
-
R2810-ONC-1423/R2810-ONC-1540
4
PRELIMINARY SCORE
ORR
ADJUSTMENTS
FINAL SCORE
F3
4
Tremelimumab
Durvalumab and platinum-based ChT
Platinum-based ChT
EMA: First-line treatment of tremelimumab in combination with durvalumab and platinum-based chemotherapy (ChT) for adult patients with metastatic non-small cell lung cancer (NSCLC) with no sensitizing epidermal growth factor receptor (EGFR) mutation or anaplastic lymphoma kinase (ALK) genomic tumor aberrations - FDA: Tremelimumab in combination with durvalumab and platinum-based ChT for adult patients with metastatic NSCLC with no EGFR mutation or ALK genomic tumor aberrations.POSEIDON
Thoracic Malignancies
Non-small-cell Lung Cancer
-
POSEIDON
4
PRELIMINARY SCORE
OS
ADJUSTMENTS
FINAL SCORE
F2a
4
Elacestrant
-
Standard-of-care endocrine therapy
Treatment of postmenopausal women, and men, with estrogen receptor (ER)‑positive, HER2-negative, locally advanced or metastatic breast cancer with an activating ESR1 mutation who have disease progression following at least one line of endocrine therapy including a CDK 4/6 inhibitorEMERALD
Breast Cancer
Breast Cancer
ER+ HER2-negative, ESR1-mutated
EMERALD
3
PRELIMINARY SCORE
PFS
ADJUSTMENTS
FINAL SCORE
F2b
3
Avelumab
-
Single arm (Phase II)
Adult patients with metastatic Merkel cell carcinoma (MCC)JAVELIN Merkel 200 (Part B - treatment-naïve patients)
Skin Cancers
Merkel cell carcinoma
-
JAVELIN Merkel 200 (Part B - treatment-naïve patients)
4
PRELIMINARY SCORE
ORR
ADJUSTMENTS
FINAL SCORE
F3
4
Trifluridine/Tipiracil (TAS-102)
Bevacizumab
Trifluridine/Tipiracil (TAS-102)
Treatment of patients with mCRC who have received two prior anticancer treatment regimens including fluoropyrimidine-, oxaliplatin- and irinotecan-based ChT, anti-VEGF agents and/or anti-EGFR agents SUNLIGHT
Gastrointestinal Cancers
Colorectal Cancer
-
SUNLIGHT
4
PRELIMINARY SCORE
OS
ADJUSTMENTS
FINAL SCORE
F2a
4
Pembrolizumab
Cisplatin or carboplatin/5-FU
Cisplatin or carboplatin/5-FU/cetuximab
In combination with platinum and 5‑fluorouracil (5‑FU) chemotherapy is indicated for the first‑line treatment of metastatic or unresectable recurrent head and neck squamous cell carcinoma in adults whose tumours express PD‑L1 with a CPS ≥ 1KEYNOTE-048
Head and neck cancer
Squamous cell
CPS PD-L1 expression ≥20
KEYNOTE-048
4
PRELIMINARY SCORE
OS
ADJUSTMENTS
FINAL SCORE
F2a
4
Pembrolizumab
Cisplatin or carboplatin/5-FU
Cisplatin or carboplatin/5-FU/cetuximab
First-line treatment of patients with metastatic or unresectable, recurrent SCCHNKEYNOTE-048
Head and neck cancer
Squamous cell
-
KEYNOTE-048
4
PRELIMINARY SCORE
OS
ADJUSTMENTS
FINAL SCORE
F2a
4
Abiraterone
ADT–docetaxel ± RT
ADT–docetaxel ± RT
De novo mHSPC (ADT with docetaxel population)PEACE-1
Genitourinary Cancers
Prostate cancer
-
PEACE-1
4
PRELIMINARY SCORE
OS
ADJUSTMENTS
FINAL SCORE
F2a
4
Abiraterone
ADT ± docetaxel ± RT
ADT ± docetaxel ± RT
De novo mHSPC (Overall population)PEACE-1
Genitourinary Cancers
Prostate cancer
-
PEACE-1
4
PRELIMINARY SCORE
OS
ADJUSTMENTS
FINAL SCORE
F2a
4
Tislelizumab
-
Chemotherapy
Indicated for the treatment of adult patients with unresectable, locally advanced or metastatic oesophageal squamous cell carcinoma after prior platinum-based chemotherapyRATIONALE 302
Gastrointestinal Cancers
Oesophageal Cancer
-
RATIONALE 302
4
PRELIMINARY SCORE
OS
ADJUSTMENTS
FINAL SCORE
F2a
4
Dostarlimab
Carboplatin and paclitaxel
Placebo + carboplatin + paclitaxel
Dostarlimab with carboplatin and paclitaxel for the treatment of adult patients with mismatch repair deficient (dMMR)/ microsatellite instability high (MSI H) primary advanced or recurrent endometrial cancer (EC) and who are candidates for systemic therapy.RUBY
Gynaecological Malignancies
Endometrial Cancer
dMMR/MSI-H
RUBY
4
PRELIMINARY SCORE
PFS
ADJUSTMENTS
FINAL SCORE
F2b
4
Cemiplimab
Platinum-based ChT
Placebo
Cemiplimab in combination with platinum-based chemotherapy for adult patients with advanced non-small cell lung cancer (NSCLC) with no EGFR, ALK, or ROS1 aberrationsEMPOWER-Lung 3
Thoracic Malignancies
Non-small-cell Lung Cancer
-
EMPOWER-Lung 3
4
PRELIMINARY SCORE
OS
ADJUSTMENTS
FINAL SCORE
F2a
4
Erdafitinib
-
ChT (docetaxel or vinflunine)
For adult patients with locally advanced or metastatic urothelial carcinoma (mUC) with susceptible FGFR3 genetic alterations, whose disease has progressed on or after at least one line of prior systemic therapy. Erdafitinib is not recommended for the treatment of patients who are eligible for and have not received prior PD-1 or PD-L1 inhibitor therapy.THOR/BLC3001 cohort 1
Genitourinary Cancers
Urothelial Carcinoma
FGFR3
THOR/BLC3001 cohort 1
4
PRELIMINARY SCORE
OS
ADJUSTMENTS
FINAL SCORE
F2a
4
Durvalumab
-
Sorafenib
Durvalumab as monotherapy indicated for the first line treatment of adults with advanced or unresectable hepatocellular carcinoma (HCC)HIMALAYA
Gastrointestinal Cancers
Hepatobiliary Cancers - Hepatocellular Carcinoma
-
HIMALAYA
4
PRELIMINARY SCORE
OS
ADJUSTMENTS
FINAL SCORE
F2c
4
Nirogacestat
-
Placebo
Nirogacestat for adult patients with progressing desmoid tumours who require systemic treatment.DeFi
Non-cancerous soft-tissue tumour
Desmoid (fibrous tissue)
-
DeFi
4
PRELIMINARY SCORE
PFS
ADJUSTMENTS
FINAL SCORE
F2b
4
Trastuzumab emtansine (T-DM1)
-
Lapatinib + capecitabine
As a single agent for the treatment of adult patients with HER2-positive, unresectable locally advanced or metastatic breast cancer who previously received trastuzumab and a taxane, separately or in combination. Patients should have either received prior therapy for locally advanced or metastatic disease, or developed disease recurrence during or within six months of completing adjuvant therapyEMILIA
Breast Cancer
Breast Cancer
HER2+
EMILIA
4
PRELIMINARY SCORE
PFS
ADJUSTMENTS
FINAL SCORE
F2b
4
Pertuzumab
Trastuzumab + docetaxel
Trastuzumab + docetaxel + placebo
HER2-positive locally recurrent unresectable or metastatic breast cancer with no prior anti-HER2 therapy or ChT for metastatic diseaseCLEOPATRA
Breast Cancer
Breast Cancer
HER2+
CLEOPATRA
4
PRELIMINARY SCORE
OS
ADJUSTMENTS
FINAL SCORE
F2a
4
Lapatinib
Trastuzumab
Lapatinib
Treatment of patients with breast cancer, whose tumours overexpress HER2 (ErbB2) in combination with trastuzumab for patients with HR- metastatic disease that has progressed on prior trastuzumab therapy of therapies in combination with ChTEGF104900
Breast Cancer
Breast Cancer
HER2+ HR-
EGF104900
4
PRELIMINARY SCORE
OS
ADJUSTMENTS
FINAL SCORE
F2a
4
Palbociclib
Fulvestrant
Fulvestrant + placebo
Patients with hormone receptor-positive, HER2-negative locally advanced or MBC who have received prior ETPALOMA-3
Breast Cancer
Breast Cancer
HR+ HER2-
PALOMA-3
4
PRELIMINARY SCORE
PFS
ADJUSTMENTS
FINAL SCORE
F2b
4
Ribociclib
Letrozole
Letrozole + placebo
Treatment of women with HR+, HER2 negative locally advanced or metastatic breast cancer in combination with an aromatase inhibitor as initial endocrine-based therapy. In pre‑ or perimenopausal women, the endocrine therapy should be combined with a luteinising hormone‑releasing hormone (LHRH) agonistMONALEESA-2
Breast Cancer
Breast Cancer
HR+ HER2-
MONALEESA-2
4
PRELIMINARY SCORE
OS
ADJUSTMENTS
FINAL SCORE
F2a
4
Panitumumab
FOLFOX4 (5-fluorouracil, leucovorin, and oxaliplatin)
FOLFOX4 (5-fluorouracil, leucovorin, and oxaliplatin)
First-line treatment of patients with wild-type RAS mCRC PRIME
Treatment of patients with EGFR-expressing, RAS wild-type mCRC CRYSTAL
Gastrointestinal Cancers
Colorectal Cancer
EGFR-expressing RAS-WT
CRYSTAL
4
PRELIMINARY SCORE
OS
ADJUSTMENTS
FINAL SCORE
F2a
4
Cetuximab
-
Best supportive care
Treatment of patients with EGFR-expressing, RAS wild-type mCRC in patients who have failed oxaliplatin- and irinotecan-based therapy and who are intolerant to irinotecan CO.17
Gastrointestinal Cancers
Colorectal Cancer
KRAS-WT
CO.17
4
PRELIMINARY SCORE
OS
ADJUSTMENTS
FINAL SCORE
F2a
4
Bevacizumab
Chemotherapy
Paclitaxel or topotecan or liposomal doxorubicin
In combination with paclitaxel, topotecan, or pegylated liposomal doxorubicin is indicated for the treatment of adult patients with platinum-resistant recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who received no more than two prior chemotherapy regimens and who have not received prior therapy with bevacizumab or other VEGF inhibitors or VEGF receptor–targeted agentsAURELIA
Gynaecological Malignancies
Ovarian Cancer
-
AURELIA
4
PRELIMINARY SCORE
PFS
ADJUSTMENTS
FINAL SCORE
F2b
4
Erlotinib
-
Carboplatin gemcitabine
Locally advanced or metastatic NSCLC with EGFR activating mutationsOPTIMAL, CTONG-0802
Thoracic Malignancies
Non-small-cell Lung Cancer
EGFR+
OPTIMAL, CTONG-0802
4
PRELIMINARY SCORE
PFS
ADJUSTMENTS
FINAL SCORE
F2b
4
Erlotinib
-
Platinum-based chemotherapy doublet
Locally advanced or metastatic NSCLC with EGFR activating mutationsEURTAC
Thoracic Malignancies
Non-small-cell Lung Cancer
EGFR+
EURTAC
4
PRELIMINARY SCORE
PFS
ADJUSTMENTS
FINAL SCORE
F2b
4
Watchlist
Tested Agent(s)
Combined Agent(s)
Control Arm
Therapeutic Indication
Tumour Type
Tumour Sub-type
Tumour Sub-group
Trial Name
Ref.
Score
Scorecard
Scorecard
This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.
For more detailed information on the cookies we use, please check our Privacy Policy.
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.